Servier has signed a drug target discovery agreement with fellowFrench firm Hybrigenics to identify new targets for novel anticancer drugs. Servier is providing several proteins to Hybrigenics, and the latter firm will use its proprietary technology to explore and map protein-protein interactions in specific cellular pathways. Servier will provide three years' funding for the project, as well as upfront cash and milestone payments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze